Immunohistochemical Evaluation of Epidermal Growth Factor Receptor (EGFR), MMP-2 and Heparanase in Pleomorphic Adenoma of Salivary Glands

Bashar Hamid, Seta Arshak Sarkis, Muna Salih Merza


Background: Salivary gland tumors are morphologically and clinically diverse group of neoplasms .The most common benign tumor
is the pleomorphic adenoma, it contains the epithelial, myoepithelial and mesenchymal component, with variable morphological
patterns. Epidermal growth factor receptor (EGFR) is a 170 KD glycoprotein which has a tyrosine kinase activity. It is found at
abnormally high levels on the surface of many types of cells, so these cells may divide excessively in the presence of epidermal
growth factor.MMP-2 is a widely studied matrix metalloproteinase which participates in extracellular matrix (ECM) degradation,
having a wide range of substrates and able to degrade type I, IV, V, VII and X collagens, laminin, elastin, fibronectin and proteoglycans.
Heparanase (HPA) is an endo-β-D-glucuronidase that has the activity of cleaving heparan sulfate (HS) side chains of heparan sulfate
proteoglycans (HSPGs), the major proteoglycans of the extracellular matrix (ECM) and basement membrane (BM) which play a key
role in preventing tumor cells invasion and metastasis.
Aims of the study: This study aimed to evaluate the expression of EGFR, MMP-2 and heparanase in pleomorphic adenoma of
salivary glands and to correlate the expression of the aforementioned biomarkers with the clinical parameters, histological subtypes
and components, and with each other as well.
Materials and methods: Twenty five paraffin blocks of pleomorphic adenoma were included in this study. Sections
immunohistochemically stained with anti EGFR, anti MMP-2 and anti heparanase monoclonal antibodies (Mabs).
Results: Positive EGFR, MMP-2 and hepranase immunohistochemical expression was found in 22 (88%), 14(56%) and 21 (84%) of
the studied cases respectively. Statistically non- significant correlation was found among the aforementioned markers with each
other, and between the markers and any of the clinical parameters and histological classifications, except a statistically highly
significant negative correlation revealed regarding EGFR expression with the squamous cells of epithelial component (p =0.001)
and a highly significant positive correlation found regarding MMP-2 expression with the chondroid stromal component (0.003).
Conclusions: Histological variation of pleomorphic adenoma has no influence on its biological behavior concerning EGFR, MMP-2
and heparanase expression. The immunoscores reorded in this study are expected to contribute to a better understanding of the
biological behavior of PA.


Ellis GL, Auclair PL.Tumors of salivary glands (Atlas

of tumor pathology) 3rd series.Fascies .Fascicle 17.

Washington, DC; Armed forces of institute of pathology;

Stennert E, Guntinas-Lichius O, Klussmann JP, Arnold

G . Histopathology of pleomorphic adenoma in the

parotid gland: prospective unselected series of 100 cases.

Laryngoscope 2001; 111(12) : 2195-2200.

Ito FA, Jorge J, VargasPA, Lopes MA. Histopathological

findings of pleomorphic adenomas of the salivary glands.

Med Oral Patol Oral Cir Bucal. 2009; 14 (2): 57-61

Downward J, Parker P, Waterfield MD “Autophosphorylation

sites on the epidermal growth factor receptor”. Nature

; 311 (5985): 483–5.

Furuse C, Miguita L, Rosa AC, Soares AB, Martinez

EF, Altemani A, de Araújo VC. Study of growth factors and

receptors in carcinoma ex pleomorphic adenoma. J Oral

Pathol Med .2010; 39(7):540-7.

Ozanne, B., Richards, C.S., Hendler, F., Burns, 0. &Gusterson

B. Over-expression of the EGF receptor is a hallmark of

squamous cell carcinomas. J. Pathol. 1986; 149: 9.

Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM.J

Clin Oncol. Matrix metalloproteinases: biologic activity

and clinical implications.2000; 18(5):1135-49.

Egeblad M, Werb Z. New functions for the matrix

metalloproteinases in cancer progression. Nat 2002;


Cawston TE, Wilson AJ. Understanding the role of tissue

degrading enzymes and their inhibitors in development and

disease. Best 2006; 20(5):983-1002.

Page-McCaw A, Ewald AJ, Werb Z. Matrix

metalloproteinases and the regulation of tissue remodelling.

Nat Rev Mol Cell Biol. 2007 Mar; 8(3):221-33.

Clark IM, Swingler TE, Sampieri CL, Edwards DR. The

regulation of matrix metalloproteinases and their inhibitors.

Int J Biochem Cell Biol. 2008; 40(6-7):1362-78.

Mott JD and Werb Z.Regulation of matrix biology by matrix

metalloproteinases Curr Opin Cell Biol. 2004; 16(5): 558–

Djonov V, Cresto N, Aebersold DM, Burri PH, Altermatt

HJ, Hristic M, Berclaz G, Ziemiecki A, Andres AC. Tumor

cell specific expression of MMP-2 correlates with tumor

vascularisation in breast cancer.Int J Oncol. 2002 Jul;


Vihinen P and Kähäri V. Matrix metalloproteinases in

cancer: Prognostic markers and therapeutic targets .INT.J

Canc .2002. ; 99 (2): 157–166

Chambers AF and Matrisian LM. Changing views of the

role of matrix metalloproteinases in metastasis. . J. Natl.

Cancer Inst. 1997; (89):1260-1270.

DeClerck YA, Imren S, Montgomery AM, Mueller

BM, Reisfeld RA, Laug WE. Proteases and protease

inhibitors in tumor progression.Adv Exp Med Biol. 1997;


Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon

R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal

I, Spector L, Pecker I . “Mammalian heparanase: gene

cloning, expression and function in tumor progression and

metastasis”. Nature Medicine .1999; 5 (7): 793–802.

Vlodavsky I, Goldshmidt O, Zcharia E et al. “Mammalian

heparanase: involvement in cancer metastasis, angiogenesis

and normal development”. Semin. Cancer Biol. (2003).

(2): 121–9.

Vlodavsky I, Ilan N, Nadir Y, Brenner B, Katz BZ, Naggi

A, Torri G, Casu B, Sasisekharan R. Heparanase, heparin

and the coagulation system in cancer progression.Thromb

Res. 2007; 120 Suppl 2:S112-20.

Neta Ilan, Michael Elkin, Israel Vlodavsky. Regulation,

function and clinical significance of heparanase in cancer

metastasis and angiogenesis.The_International_Journal_

of_Biochemistry and_Cell_Biology (2006); 38 (12), 2018-

Naka T, Boltze C, Kuester D, Schulz TO, Samii A, Herold

C, Ostertag H, Roessner A Expression of matrix

metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin

B, and urokinase plasminogen activator in non-skull base

chordoma. .Am J Clin Pathol. 2004 Dec;122(6):926-30.

Laimer K, Spizzo G, Gastl G, Obrist P, Brunhuber T, Fong

D, Barbieri V, Jank S, Doppler W, Rasse M, Norer B.

High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and

oropharynx: a TMA-based immunohistochemical analysis.

Oral Oncol. 2007 Feb;43(2):193-8.

Davidson B, Vintman L, Zcharia E, Bedrossian C, Berner

A, Nielsen S, Ilan N, Vlodavsky I, Reich R. Heparanase

and basic fibroblast growth factor are co-expressed in

malignant mesothelioma. Clin Exp Metastasis. 2004;


Takeda Y.An immunohistochemical study of bizarre

neoplastic cells in pleomorphic adenoma: its cytological

nature and proliferative activity, Pathol Int, 1999; 49; 993-

Cardesa A, Slootweg P.J.: Pathology of the Head and Neck;

Major and minor salivary glands. Springer-Verlag Berlin

Heidelberg, 2006; 5:137-147.

Ben-Izhak O, Kaplan-Cohen V, Ilan N, Gan S,

Vlodavsky I, and Nagler R. Heparanase Expression in

Malignant Salivary Gland Tumors Inversely Correlates

with Long-Term Survival. Neoplasia. 2006 ; 8(10): 879–

Ettl T, Schwarz S, Kleinsasser N, Hartmann A, T E Reichert

& Drieme O. Overexpression of EGFR and absence of

C-KIT expression correlate with poor prognosis in salivary

gland carcinomas.Histopathology 2008, 53, 567–577.

Lipari L, Mauro A, Speciale R, Gerbino A, Buscemi

M. Expression of remodelling enzymes (MMP2, MMP9)

in samples of salivary gland’s tumors. IJAE. 2010; 115, (

/2) (Supplement),

Eveson JW and Cawson RA .Salivary gland tumors .A review

of 2410 cases with particular references to histological

types ,site age and sex distribution .J Pathol,1986 ;146 :51-

ChidzongaMM ,Lopes peresVM ,Portilla Alvarez AL.

Pleomorphic adenoma of salivary glands .Clinicopathologic

study of 206 cases in Zimbabwi.Oral Surg,Oral Med,Oral

Pathol,Oral Radiol Endod ,1995;79:747-9

Williams NP,Boyd DL,Choy L,Hanchard B.Salivary

gland lesions :a Jamaican prospective.West Indian Med


Takahama A Jr, DaCrus Perez DE ,Magrin J ,.DE Almeida

OP,Kowalski LP.Giant pleomorphic adenoma of the parotid

gland .Med Oral Patol Oral Cir Bucal ,2008;13 E58-60.

Ledesma-Montest C,Garces-Ortiz M.Salivary gland tumors

in a Mexican sample.Aretrospective study.Med Oral


Paris J,Facon F,Chrestian MA ,Giovanni A,Zanaret

M.Pleomorphic adenoma of the parotid gland

:histopathological study ,Ann Otolaryngol Chir

Cervicofac,2004 ;121:161-6.

Kusafouka K,Luyten FP,De Bondt R ,Hiraki

Y,ShukunamiC,Kayano T,et al ,Immunohistochemical

evaluation of cartilage-derived morphogenic protein -1

and 2 in normal human salivary glands and pleomorphic

adenomas.Virchows Arch.2003;442:482-90

Ohtake S,Cheng J,Ida H ,Suzuki M,Ohshiro K,Zhang W,et

al .Precancerous foci in pleomorphic adenoma the salivary

glands:recognition of focal carcinoma,and atypical tumor

cells by P53 immunohistochemistry .J Oral Pathol Med

,2002 ;31 :590-7.

Kusafuka K, ,Hiraki Y,ShukunamiC, Yamaguchi A

,Kayano Takemra T .Cartilage –specific matrix protein

chondromodulin -1 is associated with chondroid formation

in salivary pleomorphic adenomas:immunohistochemical

analysis.Am J Pathol.2001;158:1465-72.

Zheng L, Fan Z, He S. A study on expression of epidermal

growth factor receptor in pleomorphic adenoma of lacrimal

gland. Zhonghua Yan Ke Za Zhi. 1995 May;31(3):212-4.

Yamada K, Iwai K, Okada Y, Mori M. Immunohistochemical

expression of epidermal growth factor receptor in

salivary gland tumours. Virchows Arch A Pathol Anat

Histopathol. 1989;415(6):523-31.

AL-Rawi NH, Al-Samarai M, Al-Kawas S, Majeed AH.

Expression of matrix metalloproteinase - MMP-2 and

tissue inhibitor TIMP-2 in intra oral pleomorphic adenoma

and adenoid cystic carcinoma . J Int Dent Med Res 2011;

: (1), pp. 1-6 .

The Expression of Matrix Metalloproteinases and Tissue

Inhibitors of Metalloproteinase in Salivary Gland Tumors.

Posted on June 20, 2010 by China Papers.

LuYann .The Expression of Matrix Metalloproteinase-2 and

Endoglin in Salivary Gland Tumors.Master thesis(2010)

Pepper MS .Role of the Matrix Metalloproteinase and

Plasminogen Activator–Plasmin Systems in Angiogenesis

. Arterioscler , Thromb Vasc Biol .2001; 21: 1104-1117

Cohen-Kaplan V, Doweck I, Naroditsky I, Vlodavsky

I, and Ilan N Heparanase augments EGF-receptor

phosphorylation: correlation with head & neck tumor

progression. Cancer Res. 2008 15; 68(24): 10077–10085.

Sternlicht MD and Werb Z.How Matrix Metalloproteinases

Regulate Cell Behavior.Annu Rev Cell Dev Biol




  • There are currently no refbacks.


Copyright by Iraqi Dental Journal

ISSN (Print): 2307-4779 | ISSN (Online): 2411-9741